The procurement of "three high" drugs in 14 provinces will start with 38 varieties...

On December 13, the Office of the Procurement Leading Group of the Alliance of Fourteen Provinces (autonomous Regions, Municipalities, and Corps) led by the Henan Provincial Medical Insurance Bureau issued the "Henan, Jin, Mongolia, Jiangxi, Guangdong, Guiyu, Gui Yu, Yunnan, Shaanxi and Qing Ningxin Corps Fourteen Provinces (districts, cities, corps) Corps) Pharmaceutical Joint Purchase Documents (Draft for Solicitation of Comments)", soliciting opinions from the public until December 15

At the same time, it also launched a trial bid for online bidding for drugs of the same type of non-medical insurance catalog with the same therapeutic effect, and issued the "Notice on Carrying out the Pilot Work for Partial Drug Bidding and Web Listing (Draft for Solicitation of Comments)"

The 14-province procurement alliance started last month.

This volume purchase consists of 13 provinces (cities, districts, and corps) including Henan, Inner Mongolia, Jiangxi, Guangdong, Guangxi, Chongqing, Guizhou, Yunnan, Shaanxi, Qinghai, Ningxia, Xinjiang, and Xinjiang Construction Corps.

On November 18, the Henan Provincial Medical Insurance Bureau announced that in order to further exert the scale effect of centralized procurement, Shanxi Province joined the inter-provincial drug procurement alliance to form the fourteen provinces (cities) , District, Corps) Pharmaceutical Purchasing Alliance.

On November 23, the Office of the Procurement Leading Group of the Alliance of Fourteen Provinces (Autonomous Regions, Municipalities, and Corps) issued the third procurement announcement.

According to the issued procurement documents (draft for comments), this centralized procurement is divided into Group A and Group B according to the relevant qualifications of the tendered varieties

The quality and efficacy consistency evaluation reference preparations (including original research drugs) issued by the State Drug Administration, the generic drugs that have passed the quality and efficacy consistency evaluation, according to the "China Food and Drug Administration on the release of chemical drug registration classification reforms" announcement of the work program "(2016, No.

If the varieties that meet the conditions of Group A are voluntarily declared to be included in Group B, the comprehensive evaluation of the enterprise and the evaluation of drug quality will be marked with full marks

The declared price of this volume purchase company shall not be higher than the company's lowest bid-winning online price on each provincial pharmaceutical procurement platform or the provincial (including inter-provincial alliance) centralized volume purchase price and benchmark price

Procurement in 14 provinces with volume adopts the "double envelope" model to evaluate bids, and the specific formula for comprehensive evaluation scores is: comprehensive evaluation score = economic and technical benchmark score × 60% + commercial benchmark score × 40%

If the overall assessment scores are tied, the companies to be selected will be determined in the following order:

1.

2.

During the procurement cycle, medical institutions should give priority to the use of selected drugs

1.

For the rest of the agreed purchase quantity, the selected product with the lowest price can be used first, or it can be used independently from all the selected products

2.
If the medical institution does not report the lowest-priced product in Groups A and B, the medical organization may use the lowest-priced product in the remaining contracted purchases in the group, or can choose to use it independently from all the selected products
.